If deal activity, capital investment and quantity of active clinical trials are any indication, the gene therapy sector will continue its growth spurt in 2021. At the end of the third quarter of 2020, 97 gene therapies had entered Phase III trials, and gene therapy financing amounts had increased by 114% year-to-date, reaching $12bn, according to data from the Alliance for Regenerative Medicine (ARM).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?